SHORT CHAIN FATTY ACIDS UPREGULATE ADIPOKINE PRODUCTION IN TYPE 2 DIABETES-DERIVED HUMAN ADIPOCYTES

PURPOSE

Short chain fatty acids (SCFAs) play a major regulatory role in adipocyte function and metabolism. The aim of this study was to investigate the effects of SCFAs on adiponectin and leptin expression in adipocytes, and also to determine whether the effects of SCFA treatment in visceral adipocytes obtained from healthy subjects are different relative to the effects in adipocytes from patients with type 2 diabetes.

MATERIALS AND METHODS

Human pericardiac preadipocytes and human pericardiac preadipocytes type 2 diabetes were differentiated into adipocytes for 21 days in 48-well plates. After differentiation, two kinds of mature adipocytes, human pericardiac adipocytes (HPAd) and human pericardiac adipocytes-type 2 diabetes (HPAd-T2D) were incubated with or without 1 mM of acetic acid (AA), butyrate acid (BA), and propionic acid (PA). After 48 hours of incubation, intracellular lipid accumulation was measured using oil red staining. In addition, mRNA levels of adiponectin, leptin and Peroxisome Proliferator-Activated Receptor γ (PPARγ) were determined by Real-Time PCR system.

RESULTS

In HPAd, SCFA supplementation did not inhibit lipid accumulation. By contrast, both AA (p<0.01) and PA (p<0.01) significantly inhibited lipid accumulation in HPAd-T2D. Regarding mRNA levels of adiponectin, no significant changes were found in HPAd, while all three types of SCFAs significantly increased (p<0.05) adiponectin expression in HPAd-T2D. Leptin mRNA expression levels were significantly increased by treatment with all three types of SCFAs in both HPAd (p<0.05) and HPAd-T2D (p<0.05).

CONCLUSION

SCFAs inhibited lipid droplet accumulation and increased mRNA expression of adiponectin and leptin in T2D-derived adipocytes.

[The surgery of thyrotropin-secreting pituitary adenomas and the significance of thyroid stimulating hormone level in follow-up]

Objective: To explore the clinical characteristics of thyrotropin-secreting pituitary adenomas and the effect of the transsphenoidal approach of procedure with/without drug treatment for thyrotropin-secreting pituitary adenomas, and to investigate the correlation between the prognosis of thyrotropin-secreting pituitary adenomas and the postoperative level of thyroid stimulating hormone (TSH). Methods: A total of 45 patients with thyrotropin-secreting pituitary adenoma who hospitalized in Peking Union Medical College Hospital from 2000 to 2015 were enrolled in the study.We collected the clinical features, hormone levels, imaging findings, treatment and follow-up data of these patients. Results: The average age of the patients was 40.26 years old and the average disease duration was 5.83 years.Among them, 8 cases were microadenomas and 37 cases were macroadenoma.Thirty patients were treated with somatostatin analogues before surgery.TSH level was significantly decreased after operation (P=0.012). All of them had done the pituitary surgery, including 44 transsphenoidal surgery and 1 subfrontal surgery that had recurrence one year after the transsphenoidal surgery.The TSH level of 34 cases went back to normal on the third day after surgery.The remission rates on three months and one year after surgery in patients with TSH level<0.1 mIU/L on postoperative day (POD) 3 were significantly higher than those in patients with TSH level>0.1 mIU/L on POD3.As well as the remission rates on three months and one year after surgery in patients with TSH level normal on postoperative one month were significantly higher than those in patients with TSH level abnormal on postoperative one month. Conclusions: TSH level of postoperative one month could be used to predict prognosis and monitor recurrence.

Elimination of blinding trachoma in China

OBJECTIVE

To present the change in the prevalence of blindness caused by trachoma between 1987 and 2006 by secondary data analysis based on two China National Sample Surveys on Disability (CNSSD).

METHODS

Secondary data analysis was performed on two China National Sample Surveys on Disability (CNSSD), which were national representative household surveys conducted in 1987 and 2006. The prevalence of blindness caused by trachoma was estimated by 10-year age group. In addition, the proportion of various causes of blindness was evaluated. The geographical distribution of blindness caused by trachoma both in 1987 and 2006 was analyzed in order to visualize the hot spots of blinding trachoma in China.

RESULTS

The prevalence of blindness caused by trachoma in China decreased from 51.5/100,000 in 1987 to 17.6/100,000 in 2006. In addition, the proportion of blindness attributed to trachoma also decreased from 10.1% (1987) to 0.9% (2006). Moreover, the prevalence of blindness caused by trachoma was over 200/100,000 in 2.2% of sampled counties in 2006 as compared to 8.6% in 1987. The hot spots of blinding trachoma were shown to be limited to underdeveloped mountain areas in Hubei and Guizhou provinces.

CONCLUSION

Although blinding trachoma is no longer the leading cause of blindness in China since the 2000's, the prevalence of trachoma should still be monitored in some underdeveloped mountain areas. Therefore, health organization must continue to fight against blinding trachoma in underdeveloped areas.

Kaleidoscope of quantum phases in a long-range interacting spin-1 chain

Motivated directly by recent trapped-ion quantum simulation experiments, we carry out a comprehensive study of the phase diagram of a spin-1 chain with XXZ-type interactions that decay as 1/r^α , using a combination of finite and infinite-size DMRG calculations, spin-wave analysis, and field theory. In the absence of long-range interactions, varying the spin-coupling anisotropy leads to four distinct and well-studied phases: a ferromagnetic Ising phase, a disordered XY phase, a topological Haldane phase, and an antiferromagnetic Ising phase. If long-range interactions are antiferromagnetic and thus frustrated, we find primarily a quantitative change of the phase boundaries. On the other hand, ferromagnetic (nonfrustrated) long-range interactions qualitatively impact the entire phase diagram. Importantly, for α ≲ 3 long-range interactions destroy the Haldane phase, break the conformal symmetry of the XY phase, give rise to a new phase that spontaneously breaks a U(1) continuous symmetry, and introduce a possibly exotic tricritical point with no direct parallel in short-range interacting spin chains. Importantly, we show that the main signatures of all five phases found could be observed experimentally in the near future.

Topological phases with long-range interactions

Topological phases of matter are primarily studied in systems with short-range interactions. In nature, however, nonrelativistic quantum systems often exhibit long-range interactions. Under what conditions topological phases survive such interactions, and how they are modified when they do, is largely unknown. By studying the symmetry-protected topological phase of an antiferromagnetic spin-1 chain with 1/r α interactions, we show that two very different outcomes are possible, depending on whether or not the interactions are frustrated. While unfrustrated long-range interactions can destroy the topological phase for α ≲ 3, the topological phase survives frustrated interactions for all α > 0. Our conclusions are based on strikingly consistent results from large-scale matrix-product-state simulations and effective-field-theory calculations, and we expect them to hold for more general interacting spin systems. The models we study can be naturally realized in trapped-ion quantum simulators, opening the prospect for experimental investigation of the issues confronted here.

Evaluation of Immune Profiles and MicroRNA Expression Profiles in Peripheral Blood Mononuclear Cells of Long-Term Stable Liver Transplant Recipients and Recipients With Acute Rejection Episodes

OBJECTIVE

This study aimed to document the difference of immunophenotypes in peripheral blood mononuclear cells (PBMCs) between long-term stable liver transplant recipients and recipients with acute rejection. We also sought to identify whether there is any correlation between microRNA (miRNA) expression profile and the differential immunoprofile in these 2 groups to establish a specific miRNA biomarker to identify potential liver transplant recipients.

METHODS

PBMCs were isolated from 53 stable liver transplant recipients (STA group) and 15 liver transplant recipients with repeated biopsy-proven rejection episodes admitted to our hospital. Immunoprofiles were analyzed by means of flow cytometry. Analysis of miRNA expression in the PBMCs was performed by means of real-time polymerase chain reaction.

RESULTS

The immune profiling analysis showed increased frequency of peripheral natural killer cells and regulatory T cells in stable liver transplant recipients compared with the acute rejection recipients and healthy volunteers (P < .05). There was no significant difference in the immune cell levels (CD19(+) B cells, CD4(+) T cells, and CD8(+) T cells) in PBMCs among the transplant recipient groups and healthy control subjects. Three miRNAs, miR-18b, miR-340, and miR-106b, were up-regulated in the PBMCs of the STA recipients compared with recipients with acute rejection.

CONCLUSIONS

These results suggest that miR-18b, miR-340, and miR-106b, which regulate the expression of specific immunophenotypes, can be used as potential biomarkers to identify long-term stable liver transplant recipients from recipients with acute rejection.

Antigen-specific T-regulatory cells can extend skin graft survival time in mice

This study investigated the effects of donor antigen-specific CD4(+)CD25(+) T-regulatory cells (Tregs) on skin allografts in mice. An allogeneic skin transplant model was established using donor C57BL/6 or DBA and recipient BALB/c mice. Recipients were divided into 4 groups: control group without intervention (CON; C57BL/6 to BALB/c), rapamycin gavage group (RAP; C57BL/6 to BALB/c), CD4(+)CD25(+) Tregs-treated group (TRE; C57BL/6 to BALB/c), in which recipients received transfusions of CD4(+)CD25(+) Tregs stimulated with C57BL/6-derived immature dendritic cells, and the third-party donor group (DBA; DBA to BALB/c) in which recipients received transfusions of BALB/c CD4(+)CD25(+) Tregs stimulated with C57BL/6-derived immature dendritic cells. Mean (SD) survival time of the skin allografts in the TRE group was 17.0 (3.4) days, significantly longer than in the other groups: CON, 6.9 (1.9) days; RAP, 10.3 (3.0) days; and DBA, 10.8 (3.6) days. The TRE group demonstrated a significantly greater expression of transforming growth factor-β and interleukin (IL)-10. Donor antigen-specific CD4(+)CD25(+) Tregs effectively extend skin allograft survival in mice.

Abstract P5-07-01: BreastCancerTrials.org: Early Evaluation of a Nationwide Clinical Trial Matching Service

Background: In 1999, UCSF researchers and patient advocates began a collaboration to design BreastCancerTrials.org (BCT.org), a web-based clinical trial matching service. In May 2005, the UCSF Center of Excellence for Breast Cancer Care (COE) and NCI launched BCT.org as a 2-year pilot with the participation of 13 Bay Area research sites. The pilot showed that breast cancer patients were willing to use an online clinical trial matching service, that they were able to enter their detailed health history onto web-based forms, and that the system's underlying caMATCH technology led to valid matches. In a companion study to evaluate the accuracy of patient-entered data, UCSF researchers found a 93% match rate between the data UCSF patients entered in BCT.org and their corresponding clinic charts. As a result, the COE partnered with a non-profit corporation (Quantum Leap Healthcare Collaborative or QLHC) to launch a nationwide version of BCT.org in October 2008. Development: The COE and QLHC team upgraded BCT.org to include personalized questionnaires for different breast conditions; the ability to use BCT.org anonymously; and the development of more clearly presented trial information. To improve the quality of matching, the team developed TrialCODE, a caMATCH-compatible tool for coding and validating a wide range of eligibility criteria. In July 2009, BCT.org added a Trial Alert Service to inform users when newly listed trials match their history, and SecureCONNECT, a messaging platform that enables users to share their online health history with research sites. COE researchers defined metrics and configured Google Analytics to monitor user traffic and support quality improvement.

Results: As of June 2010, the BCT.org trial registry had 331 coded trials, including 213 for treatment, 63 for psychosocial/support, and 55 distributed among diagnosis/screening, prevention, and other categories. The treatment trials were evenly divided between early and advanced disease and included additional trials for individuals with DCIS. In the 18 months between Jan. 2009 and June 2010, BCT.org received 25,206 visits with traffic increasing by 36% in the first 6 months of 2010 compared to the same period in 2009. Since its launch in July 2009, the Trial Alert Service (TAS) enrolled over 1,400 subscribers. As a result, the number of returning users increased from 1,335 to 4,007 in the 6-month period leading up to its launch, compared to the 6-month period after launch. Fifty research sites have registered to use SecureCONNECT and, with patient consent, can securely view BCT. org patient health histories. During the 18 month evaluation period, 3,563 BCT.org users started a health history with 2,206 (62%) completing it and matching to trials; among the users who matched to trials, 920 users (42%) clicked through to view a list of participating research sites. Conclusion: Thousands of patients have adopted BCT.org and use it to monitor trial opportunities. The registry of breast cancer trials is diverse and growing. The COE and QLHC are working to increase participation in SecureCONNECT and evaluate its impact on the efficiency of trial screening and enrollment.

Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-07-01.

Numerical analysis of deep sub-wavelength integrated plasmonic devices based on Semiconductor-Insulator-Metal strip waveguides

We report the first study of nanoscale integrated photonic devices constructed with semiconductor-insulator-metal strip (SIMS) waveguides for use at telecom wavelengths. These waveguides support hybrid plasmonic modes transmitting through a 5-nm thick insulating region with a normalized intensity of 200-300 μm(-2). Their fundamental mode, unique transmission and dispersion properties are consistent with photonic devices for guiding and routing of signals in communication applications. It has been demonstrated using Finite Element Methods (FEM) that the high performance SIMS waveguide can be used to fabricate deep sub-wavelength integrated plasmonic devices such as directional couplers with the ultra short coupling lengths, sharply bent waveguides, and ring resonators having a functional size of ≈1 µm and with low insertion losses and nearly zero radiation losses.